Drug Profile
CTS 1027
Alternative Names: CTS-1027Latest Information Update: 25 Jul 2014
Price :
$50
*
At a glance
- Originator Roche
- Developer Conatus Pharmaceuticals
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver disorders
Most Recent Events
- 25 Jul 2014 Discontinued - Phase-II for Liver disorders in Puerto Rico (PO)
- 25 Jul 2014 Discontinued - Phase-II for Liver disorders in USA (PO)
- 31 Mar 2012 CTS 1027 is no longer licensed to Conatus Pharmaceuticals (Conatus Pharmaceuticals' 2013 Form 10-K filed in March 2014)